Does Position Influence the Diagnosis of Detrusor Overactivity in a Neurological Population

NCT ID: NCT05949567

Last Updated: 2025-07-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

160 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-04-02

Study Completion Date

2026-04-02

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

ICS (International Continence Society) recommendations published in 2017 recommend performing urodynamic examinations in the sitting or standing position. These recommendations are based on a review of the literature published in 2008, which has several limitations: heterogeneous populations, old and non-harmonized techniques, and very few neurological patients. It seems appropriate to focus on neurological patients and to examine the influence of position on the detection of detrusor overactivity in these patients.

The point here is to reexamine the ICS recommendations, which are not designed for neurological patients. Indeed, many patients suffering from Multiple Sclerosis (MS) or Parkinson's disease are unable to sit or stand for the duration of the urodynamic examination. The investigators would like to assess whether exploring sphincter disorders in the supine position is still interpretable.

This would enable us to define ICS good practice recommendations for a neurological population.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

1st consultation (selection - D-15):

* Targeted questioning of disorders, completion of USP self-questionnaire, and UPDRS or EDSS scales as part of care.
* Verification of ultrasound results (for men).
* Schedule Urodynamic Assessment as part of treatment.
* Verification of eligibility criteria
* Partial information of the patient (or relative/guardian/guardian if applicable) to limit bias, and a period of reflection prior to the urodynamic test to collect consent.

On the day of the Urodynamic Assessment (D0):

* Written, free and informed consent.
* Data collection by a physician trained in the study,
* Randomization of patient to determine starting position (lying or sitting) for urodynamic assessment (via CleanWeb).
* Urodynamic assessment according to ICS recommendations, with constant filling speed over the 2 fillings (50 ml/min), water filling - Laborie machine - T-Doc system in both positions in the order defined by randomization, and printout of curves.
* Entry of socio-demographic data.
* Curves reread by a doctor who had not performed the examination and who did not know the patient or the starting position (single blind).
* Completion of the paper file by the physician reading the curves, with the following data for position 1 and position 2:
* Volume at B1 and B3 (in ml)
* Basal bladder pressure (cm / H2O)
* Occurrence of CNID or mictional reflex arc (diagnosis of detrusor overactivity)
* Volume of leakage or 1st NIDC (Uninhibited Detrusor Contraction) (ml) or
* Bladder pressure at leakage (cm / H2O)
* Maximum bladder pressure (cm / H2O)
* Paper data entry on Excel database by a trained investigator declared on the study

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Urodynamic Exam Neurologic Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

SINGLE

Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Lying position first - then sitting position

Group Type EXPERIMENTAL

urodynamic exam in sitting and lying position

Intervention Type OTHER

Urodynamic exam with 1st filling in sitting or lying position. Then , during the same procedure, a second filling in the opposite position of the 1st filling (lying or sitting)

Sitting position first - then lying position

Group Type EXPERIMENTAL

urodynamic exam in sitting and lying position

Intervention Type OTHER

Urodynamic exam with 1st filling in sitting or lying position. Then , during the same procedure, a second filling in the opposite position of the 1st filling (lying or sitting)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

urodynamic exam in sitting and lying position

Urodynamic exam with 1st filling in sitting or lying position. Then , during the same procedure, a second filling in the opposite position of the 1st filling (lying or sitting)

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient with MS or neurologically confirmed Parkinson's disease, with indication for urodynamic assessment - 1st assessment
* Clinical overactive bladder syndrome with USP overactive bladder sub-score \> or = 4 - Age ≥18 years
* In men: no prostatic hypertrophy on ultrasonography
* In women: no stress urinary incontinence (SUI); USP SUI subscore ≤ 2
* Affiliated with a social security scheme (excluding AME).
* Free and informed written consent

Exclusion Criteria

* Opposition to the performance of a Urodynamic exam as part of treatment
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Assistance Publique - Hôpitaux de Paris

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Physical and Rehabilitation Medicine Pitié Salpêtrière Hospital

Paris, France, France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Bertrand M PICHON, MD

Role: primary

142161047 ext. +33

Helene Ms Robert, MD

Role: backup

142161137 ext. +33

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

APHP230769

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.